American Diversified Holdings Corporation (ADHC) Provides Udpate on Arete Bioscience GlucoGuard Design Project
American Diversified Holdings Corporation (OTC Pink: ADHC) reported progress on its GlucoGuard device development through Arete Biosciences. The San Diego-based bioengineering firm has completed reviewing engineering schematics, patent filings, and FDA recommendations, creating a comprehensive CAD plan for the next development phase.
The upcoming phase includes finalizing product design, building a prototype for usability testing with approximately 10 participants, and conducting wearability studies as per FDA guidelines. Arete expects to complete this project phase within 7-10 days. The company also mentioned future updates regarding a DEXCOM partnership and AI implementation for hypoglycemia prediction.
American Diversified Holdings Corporation (OTC Pink: ADHC) ha comunicato i progressi nello sviluppo del dispositivo GlucoGuard tramite Arete Biosciences. L'azienda di bioingegneria con sede a San Diego ha completato la revisione degli schemi ingegneristici, delle domande di brevetto e delle raccomandazioni della FDA, elaborando un piano CAD dettagliato per la fase successiva dello sviluppo.
La prossima fase prevede la finalizzazione del design del prodotto, la realizzazione di un prototipo per test di usabilità con circa 10 partecipanti e lo svolgimento di studi sulla portabilità secondo le linee guida della FDA. Arete prevede di completare questa fase entro 7-10 giorni. L'azienda ha inoltre annunciato aggiornamenti futuri riguardanti una partnership con DEXCOM e l'implementazione di intelligenza artificiale per la previsione dell'ipoglicemia.
American Diversified Holdings Corporation (OTC Pink: ADHC) informó avances en el desarrollo de su dispositivo GlucoGuard a través de Arete Biosciences. La empresa de bioingeniería con sede en San Diego ha completado la revisión de esquemas de ingeniería, solicitudes de patente y recomendaciones de la FDA, creando un plan CAD integral para la siguiente fase de desarrollo.
La próxima fase incluye finalizar el diseño del producto, construir un prototipo para pruebas de usabilidad con aproximadamente 10 participantes y realizar estudios de portabilidad según las directrices de la FDA. Arete espera completar esta fase del proyecto en 7-10 días. La compañía también mencionó futuras actualizaciones sobre una asociación con DEXCOM y la implementación de IA para la predicción de hipoglucemia.
American Diversified Holdings Corporation (OTC Pink: ADHC)는 Arete Biosciences를 통해 GlucoGuard 장치 개발 진행 상황을 보고했습니다. 샌디에이고에 위치한 이 생명공학 회사는 엔지니어링 도면, 특허 출원 및 FDA 권고사항을 검토를 완료하고, 다음 개발 단계에 대한 포괄적인 CAD 계획을 수립했습니다.
다음 단계에는 제품 디자인 최종화, 약 10명의 참가자를 대상으로 한 사용성 테스트용 프로토타입 제작, FDA 지침에 따른 착용성 연구가 포함됩니다. Arete는 이 프로젝트 단계를 7-10일 내에 완료할 것으로 예상합니다. 또한 DEXCOM과의 파트너십 및 저혈당 예측을 위한 AI 도입에 관한 향후 업데이트도 언급했습니다.
American Diversified Holdings Corporation (OTC Pink : ADHC) a annoncé des progrès dans le développement de son dispositif GlucoGuard via Arete Biosciences. La société de bioingénierie basée à San Diego a terminé l'examen des schémas techniques, des dépôts de brevets et des recommandations de la FDA, élaborant un plan CAO complet pour la prochaine phase de développement.
La prochaine phase comprend la finalisation du design du produit, la construction d'un prototype pour des tests d'utilisabilité avec environ 10 participants, ainsi que la réalisation d'études de portabilité conformément aux directives de la FDA. Arete prévoit de terminer cette phase du projet en 7-10 jours. L'entreprise a également évoqué des mises à jour futures concernant un partenariat avec DEXCOM et l'intégration de l'IA pour la prédiction de l'hypoglycémie.
American Diversified Holdings Corporation (OTC Pink: ADHC) berichtete über Fortschritte bei der Entwicklung ihres GlucoGuard-Geräts durch Arete Biosciences. Das in San Diego ansässige Bioingenieurunternehmen hat die Überprüfung von technischen Zeichnungen, Patentanmeldungen und FDA-Empfehlungen abgeschlossen und einen umfassenden CAD-Plan für die nächste Entwicklungsphase erstellt.
Die kommende Phase umfasst die Fertigstellung des Produktdesigns, den Bau eines Prototyps für Usability-Tests mit etwa 10 Teilnehmern sowie die Durchführung von Tragekomfortstudien gemäß den FDA-Richtlinien. Arete erwartet, diese Projektphase innerhalb von 7-10 Tagen abzuschließen. Das Unternehmen kündigte außerdem zukünftige Updates bezüglich einer Partnerschaft mit DEXCOM und der Implementierung von KI zur Hypoglykämie-Vorhersage an.
- None.
- Product still in early development stages
- Multiple regulatory steps still required for FDA approval
Del Mar, California--(Newsfile Corp. - July 14, 2025) - American Diversified Holdings Corporation (OTC Pink: ADHC) is pleased to announce the San Diego based bio engineering firm ARETE BIOSCIENCES, Inc. has made strong progress on several fronts.
Arete Engineering team has reviewed all previous engineering schematics including patent filings and other intellectual property, incorporated The Food and Drug Administration's (FDA) recommendations into the design plans and created an indepth CAD plan for the next stage of development.
The next stage will include:
- Finalize the product design based on updated requirements
- Build a "looks-like" prototype suitable for a usability study with unbiased participants
- Provide an estimate to support this upcoming phase of development
Arete will be conducting an usability study including approximately ten participants to establish the wearability and comfort of the device as directed by the FDA.
It is anticipated that Arete will complete the project in the next 7 to 10 days.
Arete BioScience's team of scientists and biomechanical engineers have completed a review of GlucoGuard's foundational documentation including intellectual property, design schematics, and FDA application documentation. The team has devised a development protocol that will be initiated with the input and guidance of GlucoGuard's advisor Dr. Stephen Weber in order to facilitate the next step in the FDA approval process.
More news on the DEXCOM partnership progression, how GlucoGuard is utilizing Artificial Intelligence in predicting Hypoglycemia and other key issues will be publicized in the near term.
ABOUT ARETE BIOSCIENCES, Inc.
Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space.
Arete BioScience includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries.
ABOUT DR. STEPHEN WEBER, MD
Dr. Weber is currently an Assistant Professor at the Johns Hopkins School of Medicine. He previously served as a Medical Officer and Clinical Reviewer at The US Food and Drug Administration (FDA) and practiced medicine as an Orthopedic Surgeon for over 25 years.
ABOUT GLUCOGUARD
ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effective glucose management without disturbing the patient's rest.
ABOUT THE DIABETES MARKET
The diabetes market is poised for substantial growth, with the U.S. market valued at
The Continuous Glucose Monitoring (CGM) sector, valued at
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
www.GlucoGuardSleep.com
www.UniversalWellnessAI.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258657
FAQ
What progress has ADHC made on the GlucoGuard device development in July 2025?
How is ADHC incorporating FDA requirements into GlucoGuard development?
What is the timeline for ADHC's GlucoGuard project completion with Arete Biosciences?
How is ADHC planning to use AI technology in GlucoGuard?
What is the status of ADHC's partnership with DEXCOM?
